The cell lines were edited with CRISPR/Cas9 to create fusions of GFP with the proteins of interest, allowing researchers to image structures in real time.
The researchers said their one-step, inducible, multiplex gene knockdown and gene knockout platforms can be used in many differentiated cell types.
Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.
Knudra, a model organism engineering firm, will use CRISPR to edit C. elegans and zebrafish genomes for its pharma and biotech customers.
The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.